July 15, 2024
Adoptive Cell Therapy Market

The growing application of adoptive cell therapies in oncology is anticipated the adoptive cell therapy market

The adoptive cell therapy Market is estimated to be valued at US$ 5992.9875 Mn or 5.992 Bn in 2023 and is expected to exhibit a CAGR of 21.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Adoptive cell therapy involves extracting cells from the patient and genetically engineering them to recognize and attack cancer cells. It is used to treat different types of cancers such as lung cancer, breast cancer, renal cancer, prostate cancer, melanoma and leukemia. The main types of adoptive cell therapies are chimeric antigen receptor T-cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy. These therapies help generate antitumor activity by boosting the immune system.

Market Dynamics:

Increasing research and development for new adoptive cell therapies is expected to drive the market growth over the forecast period. For instance, Novartis received FDA approval for Kymriah, the first CAR-T cell therapy for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in young patients and relapsed or refractory large B-cell lymphoma. Various clinical trials are being conducted to expand the application of CAR-T cell therapy for other types of cancers. In addition, growing awareness about personalized cell therapy and increasing healthcare expenditure are also anticipated to fuel the adoptive cell therapy market. However, high cost associated with cell therapy development and manufacturing challenges are expected to hinder the market growth.

Segment Analysis

The global adoptive cell therapy market can be segmented into T-cell therapy, dendritic cell therapy and NK cell therapy. Among these, T-cell therapy dominates the market and accounts for the largest revenue share. This is because T-cell therapy helps boost body’s natural immune response against diseases like cancer. Some popular T-cell therapies are chimeric antigen receptor T-cell (CAR-T) therapy and T-cell receptor therapy.

PEST Analysis

Political: Governments across major countries are increasing funding for cell-based therapy research which is driving the market growth. For example, the National Cancer Institute in the US funded over US$ 150 million for CAR T-cell research in 2021.
Economic: The rising healthcare spending coupled with growing disposable income is positively impacting the market. Additionally, favorable reimbursement policies for cell therapies are further propelling the market.
Social: Increasing awareness about cell-based therapies and their advantages over conventional treatment methods is fueling their demand. Also, growing social acceptance of novel treatment options is benefiting the market.
Technological: Significant advancements in gene therapy, genome engineering and bioprocessing technologies are enabling the development of more efficient and targeted cell therapies. This is expected to drive the market during the forecast period.

Key Takeaways

The Global Adoptive Cell Therapy Market Size is expected to witness high growth, exhibiting a CAGR of 21% over the forecast period, due to increasing prevalence of cancer and other chronic diseases.

The global market size for adoptive cell therapy was valued at US$ 5992.9875 Mn in 2023 and is anticipated to reach over US$ 25,000 Mn by 2030. Factors such as availability of advanced cell processing platforms, growing focus on regenerative medicine and rising demand for personalized medicine will boost the market expansion during the forecast timeline.

Asia Pacific is projected to be the fastest growing regional market for adoptive cell therapy between 2023 and 2030 attributable to increasing healthcare investments, rise in cancer incidents, growing geriatric population and building technical expertise in emerging economies.

Key players operating in the adoptive cell therapy market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs. These players are focusing on new product launches, expansions and acquisitions to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it